Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses by Bower, Peter et al.
Greenwich Academic Literature Archive (GALA)
– the University of Greenwich open access repository
http://gala.gre.ac.uk
__________________________________________________________________________________________
Citation for published version:
Bower, Peter, Byford, Sarah, Barber, Julie, Beecham, Jennifer, Simpsoon, Sharon, Friedli, Karin, 
Corney, Roslyn, King, Michael and Harvey, Ian (2003) Meta-analysis of data on costs from trials of 
counselling in primary care: using individual patient data to overcome sample size limitations in 
economic analyses. British Medical Journal, 326 (1247). pp. 1-6. ISSN 0959 8138 (print), 1756 5833 
(online)
Publisher’s version available at:
__________________________________________________________________________________________
Please note  that  where  the  full  text  version provided on GALA is  not  the  final  published 
version, the version made available will be the most up-to-date full-text (post-print) version as 
provided by the author(s).  Where possible, or if citing, it is recommended that the publisher’s  
(definitive) version be consulted to ensure any subsequent changes to the text are noted.
Citation for this version held on GALA:
Bower, Peter, Byford, Sarah, Barber, Julie, Beecham, Jennifer, Simpsoon, Sharon, Friedli, Karin, 
Corney, Roslyn, King, Michael and Harvey, Ian (2003) Meta-analysis of data on costs from trials of 
counselling in primary care: using individual patient data to overcome sample size limitations in 
economic analyses. . London: Greenwich Academic Literature Archive.
Available at: http://gala.gre.ac.uk/4979/
__________________________________________________________________________________________
Contact: gala@gre.ac.uk
Primary care
Meta-analysis of data on costs from trials of counselling in
primary care: using individual patient data to overcome
sample size limitations in economic analyses
Peter Bower, Sarah Byford, Julie Barber, Jennifer Beecham, Sharon Simpson, Karin Friedli, Roslyn
Corney, Michael King, Ian Harvey
Abstract
Objective To assess the feasibility of overcoming
sample size limitations in economic analyses of
clinical trials through meta-analysis of data on
individual patients from multiple trials.
Design Meta-analysis of individual patient data from
trials of counselling in primary care compared with
usual care by a general practitioner.
Setting Primary care.
Patients People with mental health problems.
Main outcome measures Direct treatment costs,
depressive symptoms, and cost effectiveness.
Results Meta-analysis of individual patient data
proved feasible. The results showed that the previous
analyses of individual trials were underpowered to
provide useful conclusions about the cost
comparisons. The results are sensitive to assumptions
made about the costs of sessions with a counsellor
and the management of patients by a general
practitioner.
Conclusions Meta-analysis of individual patient data
may assist in overcoming sample size limitations in
economic analyses. Although feasible, such analysis
has shortcomings that may limit the validity of the
results. The relative costs and benefits of this method,
as opposed to further collection of primary data, are
as yet unclear.
Introduction
Economic evaluation is an increasingly important ele-
ment of clinical trials. Several aspects of economic
evaluations can make their addition to clinical trials
problematic, but of particular importance is the sample
size requirement.1 2 Trials are generally powered to
detect clinically significant differences in outcomes, but
since costs are often characterised by higher variability
and skewness than clinical outcomes,3 economic analy-
ses may be underpowered, resulting in type II errors—
that is, failure to reject the null hypothesis that there is
no difference in costs between treatments.
A recent example of this concerns counselling in
primary care. Four trials reported no evidence of
differences in the total costs of patients treated by
counsellors compared with those who remained under
the usual care of a general practitioner.4–7 None of
these trials were powered on costs, however, so that
firm conclusions about costs cannot be drawn. An
adequately powered trial could be conducted, but this
would need to be large, would be costly, and would
delay access to relevant information for several years.
An alternative solution is to pool existing data in a
meta-analysis. Analyses of data on individual patients
are considered the gold standard for this technique
and have several advantages, such as ensuring quality
of randomisation and intention to treat analyses,8 but
in the present context the primary advantage would be
in increasing the sample size for economic evaluation
and overcoming the limitations of previous analyses.
We examined the feasibility of meta-analysis of
economic data, using individual patient data on
healthcare utilisation from trials of counselling in
primary care.
Methods
Studies were identified from a Cochrane systematic
review. Seven trials met the Cochrane eligibility
criteria.9 Three studies were excluded after examina-
tion; two reported data on healthcare utilisation, but
neither provided adequate detail.10–12 The random-
isation procedures of these studies were of poor quality
and likely to be associated with bias.9 The third trial is
yet to report economic data but also used a
comparison group of antidepressant treatment pre-
scribed by a general practitioner rather than usual care
by a general practitioner.12 This trial was also excluded,
given that management by a general practitioner (and
associated costs) were likely to be significantly different.
Table 1 lists the included studies.4–7
Pooling data using meta-analysis requires studies to
be broadly comparable, but the degree of legitimate
difference is contentious.13 All four studies used coun-
sellors meeting the criteria for accreditation by the
British Association for Counselling and Psycho-
therapy, although the exact models of counselling dif-
fered (for example, non-directive, psychodynamic). In
three studies, general practitioners recruited patients,
whereas in the fourth patients were screened, and the
trial was restricted to patients with chronic problems of
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six months or more. The time of follow up varied from
three to 12 months.
Identification of comparable data
Costs
The perspective taken for the analysis was that of the
healthcare system, and only direct healthcare costs
were analysed. Available data on the utilisation of
health care varied, but all trials included consultations
with a general practitioner, prescriptions for psycho-
tropics, and mental health referrals, which are the
sources of cost most likely to be influenced by the pro-
vision of counselling (see table 1). Patient specific data
were collected from medical records and patient self
report.
Consultations—Not all trials collected data on all
types of consultations in primary care, so consultations
had to be limited to surgery attendances only, whereas
other types of consultations, such as home visits or
appointments with a practice nurse, were excluded.
Drugs—Recording of data on drugs varied. Two
studies reported exact dosage and duration of use of all
drugs, which allowed calculation of number of tablets
prescribed and a cost per tablet to be applied. The
remaining two trials recorded only whether a prescrip-
tion for relevant psychotropics had been given. Stand-
ard duration of use and dosage for tricyclics, selective
serotonin reuptake inhibitors, and anxiolytics were
therefore imputed. Data on other drugs were excluded.
Mental health referrals—Data on mental health refer-
rals also varied and were recoded as the number of
attendances at four categories of services: inpatient
psychiatry, outpatient psychiatry (including commu-
nity mental health teams and psychotherapy), practice
based psychological therapy (for example, psycholo-
gists and counsellors in primary care), and other
providers of psychological therapy in community and
voluntary groups, such as Relate and self help groups.
Practice based psychological therapy (provided to
patients in both groups as part of usual care by a gen-
eral practitioner) was differentiated from protocol
therapy (provided to the experimental group only). It
was assumed that all protocol therapy sessions were
completed in the first six months of the trial.
Data collection periods—The time periods covered by
data collection varied (see table 1). Where required,
costs were adjusted to represent standard periods of six
months, allowing comparative analysis in the short
term (six months after baseline) for all four trials and in
the long term (12 months after baseline) for three
trials. These adjustments assumed that service use
remained constant over time and were applied to all
variables apart from protocol therapy, since the length
of such therapy in all trials was fixed.
Effectiveness
In three studies the Beck depression inventory was the
primary outcome measure.4 5 7 14 As with the cost data,
clinical outcome data were collected at different
periods (three, four, and six months for short term data
and nine and 12 months for long term data). However,
no attempts were made to adjust these data to standard
periods of six months. The results may thus be subject
to bias if differential outcomes between treatments
change over time. Only one trial included a generic
health status preference instrument.4
Calculation of costs
We applied standardised national unit costs for the
financial year 1999-2000 to the data on utilisation of
healthcare services (table 2). The costs of drugs were
based on the British National Formulary, using the
cheapest alternative available.15 Costs of protocol
therapy and practice based counselling services were
based on salary figures provided by a relevant national
organisation (Counsellors and Psychotherapists in Pri-
mary Care). All relevant costs incurred by employers
were included, plus capital and direct overheads (data
not shown). All other costs were based on figures from
the Personal Social Services Research Unit.16 Discount-
ing was unnecessary as costs were all within the same
time period and were not recorded beyond 12 months.
Data analysis
Not all trials reported long term data or usable
effectiveness outcomes, and there were missing data in
all studies. Therefore, the data available varied for
analyses of costs alone, effectiveness alone, and cost
effectiveness. Missing data on costs in the long term
were not associated with randomised group, sex, or
employment status in any trial but were associated with
baseline score on the Beck depression inventory, age,
and marital status in one trial in each case.Missing data
Table 1 Studies of counselling in primary care included in review
Study Type of counselling Patient inclusion criteria Follow up
Main clinical
outcome Data on service use Sample size
King et al4 Non-directive Depression or mixed
anxiety and depression,
where brief psychological
intervention was indicated.
Minimum score ≥14 on
Beck depression inventory
4 and 12 months Beck depression
inventory
Consultations,
psychotropic
prescriptions, all
referrals
134
Harvey et al6 Method not standardised Any emotional or
relationship problem,
irrespective of previous
mental health history
4 months Hospital anxiety
and depression
scale
Consultations, all
prescriptions, all
referrals
162
Simpson et al7 Psychodynamic or
cognitive behavioural
Mild to moderate
depression of six months
or more. Minimum score
≥14 on Beck depression
inventory
6 and 12 months Beck depression
inventory
Consultations, all
prescriptions, all
referrals
181
Friedli et al5 Non-directive Emotional difficulty
deemed to require brief
psychotherapy, onset of
difficulties in past six
months
3 and 9 months Beck depression
inventory
Consultations, all
prescriptions, all
referrals
136
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on effectiveness were imputed using the last observa-
tion carried forward. Figure 1 shows the data available
for the analyses.
Data on costs and outcomes were pooled
separately in a fixed effects meta-analysis.17 This
combines estimates of treatment effects from the indi-
vidual trials into an overall weighted average, with
weights given by the inverse of the variance of the dif-
ference in means for each trial. A fixed effects analysis
was preferred because of the small number of trials
available; however, these results were compared with
those from random effects models. A test for
heterogeneity was also conducted, although this may
lack power given the small number of trials available.
Analyses were conducted separately for the total direct
costs and the total primary care costs, to enable
primary care commissioners to assess the economic
impact on their sector alone. All analyses were carried
out with Stata (Release 7).
Meta-analysis assumes that the overall treatment
effect is normally distributed. Costs were not normally
distributed, but the validity of the results was confirmed
using non-parametric bootstrapping.18 Such an
approach was preferred to transformation or non-
parametric tests, as it allows inference about the popu-
lation mean.19
Relative cost effectiveness was described using
incremental cost effectiveness ratios, the ratio of differ-
ential average costs of the two interventions to the dif-
ferential average effects.20 21 Cost effectiveness accept-
ability curves were also calculated for both the short
term and the long term. These plot the probability that
counselling is cost effective compared with usual care
by a general practitioner for a range of possible maxi-
mum values (the ceiling ratio) a decision maker might
be willing to pay for an improvement in the Beck
depression inventory score. The curves are based on an
estimate of the joint distribution of difference in mean
cost and difference in mean Beck depression inventory
score obtained using bootstrapping.20–22 These curves
incorporate the uncertainty that exists around the esti-
mates of mean costs and effects as a result of sampling
variation and uncertainty on the maximum cost effec-
tiveness ratio that a decision maker would consider
acceptable.
Results
Cost outcomes
The main analysis of costs over the long term indicated
that counselling was associated with significantly
greater total direct costs per patient (weighted
difference in means £110 ($177; €154), 95% confi-
dence interval £38 to £182; fig 2) and primary care
costs per patient (£146, £110 to £183) than usual care
by a general practitioner. No evidence was found of
heterogeneity (total costs P=0.70; primary care costs
P=0.83), and random effects analysis gave similar
results.
In the short term, counselling was again associated
with significantly greater total direct costs per patient
(£92, £57 to £126; fig 3) and primary care costs per
patient (£135, £114 to £156) than usual care by a gen-
eral practitioner. Some evidence was found of
heterogeneity in the analysis of primary care costs
(2=7.2, df=3, P=0.07). Interpretation is not substantially
different if based on the results of random effects
analysis (£133, £99 to £167).
Table 2 Unit costs used in analysis
Service (description) Source of costs Unit costs (£)
Consultation with general practitioner (per surgery consultation) Personal Social Services Research Unit 18
Inpatient psychiatry (per inpatient day) Personal Social Services Research Unit 146
Outpatient psychiatry (per outpatient attendance) Personal Social Services Research Unit 107
Community psychiatry (home visit by community psychiatric nurse) Personal Social Services Research Unit 21
Voluntary groups (voluntary day care) Personal Social Services Research Unit 17
Protocol therapy and practice based mental health treatments (per therapy session) Salary scales for Counsellors and Psychotherapists in
Primary Care
30
£1.00 ($1.61; €1.40).
Prescription costs were from British National Formulary and are not reproduced here.
Short term follow up
613 patients from four trials
Short term cost
510 patients from four trials
(17% missing)
Short term cost and
effectiveness data
378 patients from three trials
(16% missing)
Short term effectiveness
395 patients from three trials
(12% missing and imputed)
Long term follow up
451 patients from three trials
Long term effectiveness
375 patients from three trials
(17% missing and imputed)
Long term cost and
effectiveness data
350 patients from three trials
(22% missing)
Long term cost
350 patients from three trials
(22% missing)
Total available data
613 patients randomised
in four trials
Fig 1 Data available for analyses
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Sensitivity analysis
Examination of the cost components indicated that the
costs of consultations with a general practitioner and
costs of protocol therapy were the main drivers of
direct costs. Therefore, post hoc sensitivity analyses
were conducted, systematically changing these
variables.
Duration of general practitioner consultations—It has
been suggested that referral to a counsellor may
reduce the time general practitioners spend consulting
with patients, as well as the overall rate of consulting.23
Therefore the effect of selectively increasing the dura-
tion of consultations in the group receiving usual care
was tested in a threshold analysis. The significant
differences found in total direct costs in the long term
became non-significant (£72, − £1 to £145) when the
duration of a consultation for the control group was
increased to 11.75 minutes, equivalent to a 26%
increase in the cost of a consultation.
Cost of protocol therapy—The cost of protocol therapy
was based on the average of three different grades,
ranging from standard counsellors to those in more
senior management positions. It is likely that more
counsellors in primary care are paid at the lower grade,
in contrast to the counsellors employed within the
trials included in our study. When costs for counselling
sessions were reduced to those of the least expensive
counsellor, the differences between the groups in total
direct costs in the long term became non-significant
(£69, − £1 to £139).
Effectiveness outcomes
Counselling produced superior scores on the Beck
depression inventory in the short term (1.93, 0.14 to
3.71) but not in the long term (1.16, − 0.65 to 2.97).
Some evidence was found of heterogeneity in the short
term data (2=7.3, df=2, P=0.03). The results using
random effects analyses were similar.
Cost effectiveness analysis
The analysis of cost effectiveness was based on patients
with data available on both cost and effectiveness. The
incremental cost effectiveness ratio for counselling
compared with usual care by a general practitioner
over the long term was £196 per one point
improvement on the Beck depression inventory (coun-
selling minus usual care incremental mean cost £110,
incremental mean effect 0.56). Figure 4 illustrates the
uncertainty associated with the costs and effects of the
two treatments in the long term, and shows that for
willingness to pay values above £196, counselling has a
greater than 50% probability of being cost effective
compared with usual care by a general practitioner.
The probability of counselling being more cost
effective than usual care stabilises at about 69% for
willingness to pay ratios greater than £2000.
The incremental cost effectiveness ratio for
counselling compared with usual care by a general
practitioner in the short term was £50 per one point
improvement on the Beck depression inventory (coun-
selling minus usual care incremental mean cost £109,
incremental mean effect 2.16).
Discussion
Meta-analysis of individual patient data can be used to
overcome the sample size limitations often associated
with economic analyses. The analyses may, however, be
limited in several ways. The need to identify
comparable data and apply standardised costs means
that detail in individual studies may be lost. For exam-
ple, non-psychiatric referral and drug costs were
ignored, as were distinctions between particular
services, such as between outpatient psychiatry and
community mental health teams. The lack of data on
costs of lost production meant that advantages associ-
ated with either treatment in returning people to work
had been ignored. However, none of these issues may
be as central to the effects of counselling (or as likely to
show effects) as the measures of depressive symptoms
and utilisation of mental health services.
Study
King et al (2000)4
Simpson et al (2000)7
Friedli et al (2000)5
Overall
Test for heterogeneity: χ2=0.72, df=2, P=0.70
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We found significant variation between trials in
standard deviations of costs. This may reflect more
comprehensive estimates of service use in some trials,
or differences between trials in the availability of
certain services (for example, treatment for mental
health outside the trial). Such differences have
important implications for standard meta-analysis
approaches, where estimates are weighted inversely by
their assumed precision. Cost sources omitted or
imputed in the current analysis would have also
increased variance further if they had been measured.
Adjusting costs to represent common time periods
assumes service use is linear over time, when it may be
that service use (such as consultation rates and drug
use) reduces when an effective therapy is provided.
Such methodological compromises mean that the
present analysis can never approach the precision of
primary data collection. However, it is a matter of
debate (and economics) whether this additional preci-
sion is worth the extra cost and time delay required to
fund an adequately powered economic analysis, or
whether secondary analysis provides a reasonably
accurate estimate to inform policy and practice.
One compromise in future research is to attempt
to ensure greater comparability in methodology in
studies examining common cost effectiveness ques-
tions, through the use of the same outcome measures
and the collection of data on service use on the same
range and type of services. The prospective regis-
tration of trials might facilitate this. Researchers in the
United States have gone further in explicitly preplan-
ning meta-analyses of different interventions, deliber-
ately standardising across studies where possible and
identifying methods to deal with methodological
heterogeneity.24
Several statistical issues also arise in meta-analyses
of cost data. Specific features of economic outcomes
(for example, skewness in the distribution of cost data)
mean that further investigation into appropriate statis-
tical methodology is needed.
Costs are affected particularly by missing data.25
Analysis of individual patient data allows imputation of
missing values through several methods. Recent
approaches that more accurately reflect the uncer-
tainty associated with imputation of missing data have
been described but were beyond the scope of our
study.25 Data were also lost for the cost effectiveness
analysis owing to use of different effectiveness
measures in trials. In cases where outcomes are
conceptually the same but measured on different
scales, the meta-analysis approach of standardised dif-
ferences might be used, allowing all trials to be
included in the analysis.
Cost effectiveness of counselling
Caution should be exercised in drawing specific
conclusions about the cost effectiveness of counselling,
given that the validity of the current methodology is
unclear. However, the main results indicate that the
costs associated with counselling were higher than
those with usual care by a general practitioner, which
supports the argument that previous analyses were
underpowered to detect these effects.2 The interpret-
ation of figure 4 is complex, because typical ceiling
ratios for a one point change in scores on the Beck
depression inventory are not known. Such ratios are
often assigned to quality adjusted life years (QALYs),
but methods for translating Beck depression inventory
scores into QALYs are crude at present.26
Given these limitations, the main analysis of differ-
ences in costs alone may be easier to interpret. These
differences were found to be sensitive to increases in
the duration of consultations with a general
practitioner in patients not referred for counselling.
However, no trials reported objective measures of
duration of consultation, and thus this effect is
speculative.
Results were also sensitive to the costs of
counselling sessions. Tension exists between the desire
to provide high quality counselling services by employ-
ing experienced (and thus more expensive) counsel-
lors and the need to ensure that session costs do not
jeopardise cost effectiveness. This has implications for
other psychological therapies in primary care, such as
cognitive behavioural therapy, where session costs may
be even higher.4 Our findings may provide an
additional stimulus to the development of “minimal”
interventions, which reduce or remove the need for the
therapist, if effectiveness can be maintained.26 27
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